



Ojjaara in Saudi Arabia

The SFDA named-patient coordination pathway — indicative 2026

ONCOLOGY · MYELOFIBROSIS WITH ANAEMIA

The clinical situation

Ojjaara (momelotinib) is an oral JAK1/JAK2/ACVR1 inhibitor FDA-approved for adults with intermediate or high-risk myelofibrosis (primary MF, post-PV MF, post-ET MF) and anaemia. Manufactured by GSK. The ACVR1 activity improves anaemia through hepcidin suppression, addressing a persistent unmet need in the JAK-inhibitor class. Dosing is 200 mg once daily. Pre-treatment workup covers CBC, LFTs, hepatitis B screen, TB screen, and IPSS/DIPSS risk scoring per FDA labelling.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your haematologist documents MF subtype, risk score, transfusion burden, anaemia status, and Ojjaara rationale.
- 2 Baseline workup.** CBC, LFTs, HBV/TB screen, bone marrow review per FDA labelling.
- 3 SFDA named-patient application.** Physician or hospital pharmacy files clinical rationale, patient reference, and chain-of-custody commitment.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner with controlled-ambient shipment.
- 5 Arrival & first dose.** Dispensing pharmacy releases the first 30-day supply; monthly refill cadence and monitoring established.

Indicative economics

Reference US cash-pay range: USD 22,000–26,000 per month of Ojjaara (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete SFDA application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody from GSK authorised distribution.

Documentation. Physician kit tailored to SFDA review, with MF risk-score and anaemia-focused rationale annex. **Logistics.** Controlled-ambient internationally tracked shipment. **Concierge case lead.** Named point of contact for family and physician through monthly refills. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Ojjaara × Saudi Arabia first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/ojjaara-saudi-arabia.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team